ライブラリ登録: Guest
Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集
Critical Reviews™ in Immunology
インパクトファクター: 1.352 5年インパクトファクター: 3.347 SJR: 0.657 SNIP: 0.55 CiteScore™: 2.19

ISSN 印刷: 1040-8401
ISSN オンライン: 2162-6472

巻:
巻 39, 2019 巻 38, 2018 巻 37, 2017 巻 36, 2016 巻 35, 2015 巻 34, 2014 巻 33, 2013 巻 32, 2012 巻 31, 2011 巻 30, 2010 巻 29, 2009 巻 28, 2008 巻 27, 2007 巻 26, 2006 巻 25, 2005 巻 24, 2004 巻 23, 2003 巻 22, 2002 巻 21, 2001 巻 20, 2000 巻 19, 1999 巻 18, 1998 巻 17, 1997 巻 16, 1996 巻 15, 1995 巻 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v29.i6.10
pages 443-468

Regulation of Allergy with RNA Interference

Motohiko Suzuki
Departments of Surgery and Pathology, University of Western Ontario, London, Ontario, Canada; Department of Otorhinolaryngology, Nagoya City University, Nagoya, Japan
Xiufen Zheng
Departments of Surgery and Pathology, University of Western Ontario, London, Ontario
Xusheng Zhang
Departments of Surgery and Pathology, University of Western Ontario, London, Ontario
Yuwei Zhang
Medistem Laboratories, San Diego, CA
Thomas E. Ichim
Departments of Surgery and Pathology, University of Western Ontario, London, Ontario, Canada; Medistem Laboratories, San Diego, CA
Weiping Min
Departments of Surgery and Pathology, University of Western Ontario, London, Ontario

要約

Allergic diseases such as asthma, allergic rhinitis, allergic conjunctivitis, and atopic dermatitis are clinically challenging. Although current treatments such as antihistamines, leukotriene receptor antagonists, and corticosteroids are effective at reducing symptoms, they do not address the underlying cause of the allergic response. Therefore, novel therapies that target upstream causative events in allergic diseases are desirable. The induction of RNA interference (RNAi) by small interfering RNA (siRNA) is a potent method for specifically knocking down molecular targets. Gene modulation by siRNA is therapeutically promising, with clinical safety and feasibility already demonstrated. However, to our knowledge, the use of siRNA in the area of allergic disease has been limited. Recently, we demonstrated the inhibition of CD40 by siRNA as a means of inhibiting allergic reactions. RNAi-based therapies represent a novel and promising strategy for the control of both the symptoms of allergy and the cause of the allergic response. Here we discuss the potential of siRNA in the treatment of allergic diseases by focusing on molecular and cellular interactions involved in the allergic cascade.


Articles with similar content:

New Approaches to Antigen Delivery
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.17, 2000, issue 3
David FitzGerald, Randall J. Mrsny
Small RNAs: The Qualified Candidates for Gene Manipulation in Diverse Clinical Pathologies
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.31, 2014, issue 4
Gaurav Sharma, Kanwaljit Chopra, Indu Pal Kaur, Parveen Rishi, Sanjeev Puri
Shigellosis: Innate Mechanisms of Inflammatory Destruction of the Intestinal Epithelium, Adaptive Immune Response, and Vaccine Development
Critical Reviews™ in Immunology, Vol.23, 2003, issue 5-6
P. J. Sansonetti, Armelle Phalipon
Molecular Interactions Between Dendritic Cells and Salmonella: Escape from Adaptive Immunity and Implications on Pathogenesis
Critical Reviews™ in Immunology, Vol.25, 2005, issue 5
Mirentxu I. Iruretagoyena, Alexis M. Kalergis, Jaime A. Tobar, Susan M. Bueno
Driving Cytotoxic Natural Killer Cells into Melanoma: If CCL5 Plays the Music, Autophagy Calls the Shots
Critical Reviews™ in Oncogenesis, Vol.23, 2018, issue 5-6
Muhammad Zaeem Noman, Markus Ollert, Ludovic Menard, Malina Xiao, Bassam Janji, Martyna Szpakowska, Andy Chevigne, Guy Berchem, Manon Bosseler